1190423-36-9

Usage

Uses

Used in Pharmaceutical Industry:
2-(N,N-BisBOC-Amino)pyrimidine-5-boronic acid, pinacol ester is used as a reagent for the synthesis of pyrrolotriazine derivatives, which act as PI3 kinase inhibitors. These inhibitors are crucial in the development of drugs targeting cancer cells and other diseases related to the dysregulation of the PI3 kinase pathway.
Additionally, 2-(N,N-BisBOC-Amino)pyrimidine-5-boronic acid, pinacol ester is used in the preparation of heteroaryl carbazoles, which are inhibitors of Hsp82 and Hsp90 proteins. These inhibitors have potential applications in treating cancer by targeting heat shock proteins, which play a significant role in the survival and proliferation of cancer cells.

Upstream product

• 264600-82-0 2-(di-(tert-butoxycarbonyl)amino)pyrimidine 
• 73183-34-3 bis(pinacol)diborane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1173206-16-0 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine 

Downstream Products

• 1374261-15-0 5-{3-[4-(1-aminocyclobutyl)phenyl]-9H-imidazo[1,2-d]pyrido[2,3-b][1,4]benzodiazepin-2-yl}pyrimidin-2-amine 
• 1190423-38-1 C₃₃H₃₀FN₅O₄ 
• 1190423-39-2 2-methylpropan-2-yl [5-(9-{4-carbamoyl-3-[(4-trans-hydroxycyclohexyl)amino]phenyl}-9H-carbazol-4-yl)pyrimidin-2-yl]carbamate 

Relevant academic research and scientific papers

Two Ligands Transfer from Ag to Pd: En Route to (SIPr)Pd(CF2H)(X) and Its Application in One-Pot C-H Borylation/Difluoromethylation

A process for the concurrent transfer of both the NHC ligand and the difluoromethyl group from [(SIPr)Ag(CF2H)] to PdX2 (X = Cl, OAc, and OPiv) for the preparation of [(SIPr)Pd(CF2H)X] complexes is described. These complexes were air-stable and easily underwent transmetalation with aryl pinacol boronate/reductive elimination to generate ArCF2H in high yields. Based on this discovery, the first one-pot C-H borylation and difluoromethylation process for the preparation of difluoromethylated (hetero)arenes was developed.

NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF

The invention relates to the novel substances in Formula (I): wherein Het is a heterocycle optionally substituted by one or a plurality of radicals R1 or R′1; R is selected from the group comprising Formula (A′), (B), (C), (D), or (E), with R1 and/or R′1 selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxyl, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalcoxy, alkylhio, or carboxy that is free or esterified by an alkyl, carboxamide, CO—NH(alkyl), CON(alkyl)2, NH—CO-alkyl, sulfonamide, NH—S02-alkyl, S(0)2-NHalkyl, or S(02)-N(alkyl)2 radical; all these radicals are optionally substituted; W1, W2, and W3 independently are CH or N; X is 0, S, NR2, C(O), S(O), or S(0)2; Z is optionally substituted H, Hal, -0-R2 or —NH—R2 with R2 being H, alkyl, cycloalkyl, or heterocycloalkyl; and these substances are all isomeric forms and salts thereof, used as drugs.

1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER

The invention provides a family of 1,4-benzodiazepinone compounds and methods for their use as therapeutic agents in treating cancer. Pharmaceutical compositions and methods of making the 1,4-benzodiazepinone compounds are provided.